Global Licensing Deal Sees Halozyme and Skye Bioscience Partner on Nimacimab-ENHANZE® Obesity Program
Halozyme Therapeutics, Inc. and Skye Bioscience, Inc. have disclosed that they entered into a non-exclusive worldwide collaboration and licensing arrangement in December 2025. As part of this agreement, Skye has obtained rights to use Halozyme’s ENHANZE® drug delivery platform to develop and potentially commercialize a subcutaneous version of nimacimab for obesity treatment.
The agreement is designed to enable Skye to study higher subcutaneous doses of nimacimab by allowing administration through increased injection volumes. This approach is intended to support broader dose-ranging evaluations as part of Skye’s development program.
Halozyme’s President and Chief Executive Officer, Dr. Helen Torley, stated that the collaboration extends the application of the ENHANZE technology into the obesity field, highlighting its adaptability across different therapeutic uses and its role in supporting the company’s long-term royalty-based growth strategy.
Skye Bioscience President and Chief Executive Officer, Punit Dhillon, noted that assessing higher doses of nimacimab requires a feasible subcutaneous delivery method. He explained that working with Halozyme provides an established technology to explore multiple dosing strategies, including studies involving combination use with GLP-1 receptor agonists.
Under the terms of the agreement, Skye will make milestone-based payments linked to specific development and commercialization achievements. Halozyme is also eligible to receive mid-single-digit royalty payments on net sales of nimacimab products developed using the ENHANZE® technology for a minimum period of ten years.
Skye expects to begin a Phase 2b clinical study in obesity for nimacimab formulated with ENHANZE® around mid-2026. The planned trial will also examine the use of nimacimab in combination with a GLP-1 receptor agonist.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.
Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.
Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1.
